EdiGene
Biotechnology
Hurun Global Cheetahs 2024No open roles listed
Data updated Nov 22, 2026Money ledger: 2 records from 2 sourcesAnnounced 2Full reportReport a mistake
Lately:1 news story in 90 daysFollow changes →
Facts
as of Nov 22, 2026EdiGene是一家生物技术公司,其使命是将前沿的基因组编辑技术转化为治疗遗传病和癌症的新疗法,并将其转化为创新的解决方案,以推进药物发现。我们利用我们的专有平台来开发针对一系列疾病的基因编辑疗法,并进行高通量的基因组筛选,以便能够在生物学环境中剖析功能性大数据。.
- Headquarters
- Beijing, China
- Employees
- 201-500estimated range
- Website
- edigene.com
These are the key facts about EdiGene on Alion as of Nov 22, 2026. EdiGene is headquartered in Beijing, China. It has raised $129M in 2 funding rounds. The latest round is Series B of $62M, announced in 2021.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
Funding
Full ledger, 2 records →EdiGene has $129M paid in by investors, lenders and donors.
$129MPaid in
Money innewest first
$62MPaid
$67MPaid
Money by yearUSD, rounds and grants
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
Products
Products →EdiGene has 1 clinical trials on record, 1 under way.
Clinical trials
A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus
phase 1 · under way · 12 participants · Lupus Erythematosus, Systemic
Jul 2024
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
Risk
Full record →EdiGene in public registers.
No match
None
Patents
4
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| Beijing China | Headquarters | 0 |
Source: office addresses in postings and company registers
Milestones
Apr 20, 2021
Raised a round Series B $62M
Oct 12, 2020
Raised a round Series B $67M
Each milestone is dated by its source: registers, filings, the press
Lists and programmes
Newsroom
Oct 12026
News · pharmtech.com
Abcam has acquired the entire live cell line and lysates portfolio of gene-editing therapy developer, EdiGene.
Sources: the outlets named on each headline, each story once
